-+ 0.00%
-+ 0.00%
-+ 0.00%

Dongcheng Pharmaceutical announced that the holding subsidiary Zhongtai Biotech underwent on-site inspections by the US Food and Drug Administration from July 17 to July 18, 2026. Recently, it received an on-site inspection report issued by the FDA and passed the on-site inspection with zero “483” NAI defects.

Zhitongcaijing·09/11/2026 11:41:15
Listen to the news
Dongcheng Pharmaceutical announced that the holding subsidiary Zhongtai Biotech underwent on-site inspections by the US Food and Drug Administration from July 17 to July 18, 2026. Recently, it received an on-site inspection report issued by the FDA and passed the on-site inspection with zero “483” NAI defects.